Literature DB >> 20237413

Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance.

Julien Cherfils-Vicini1, Sophia Platonova, Mélanie Gillard, Ludivine Laurans, Pierre Validire, Rafaele Caliandro, Pierre Magdeleinat, Fathia Mami-Chouaib, Marie-Caroline Dieu-Nosjean, Wolf-Herman Fridman, Diane Damotte, Catherine Sautès-Fridman, Isabelle Cremer.   

Abstract

Compelling evidence suggests that inflammation, cell survival, and cancer are linked, with a central role played by NF-kappaB. Recent studies implicate some TLRs in tumor development based on their ability to facilitate tumor growth; however, to our knowledge, involvement of neither TLR7 nor TLR78 has yet been demonstrated. Here we have demonstrated expression of TLR7 and TLR8, the natural receptors for single-stranded RNA, by tumor cells in human lung cancer in situ and in human lung tumor cell lines. Stimulation with TLR7 or TLR8 agonists led to activated NF-kappaB, upregulated expression of the antiapoptotic protein Bcl-2, increased tumor cell survival, and chemoresistance. Transcriptional analysis performed on human primary lung tumor cells and TLR7- or TLR8-stimulated human lung tumor cell lines revealed a gene expression signature suggestive of chronic stimulation of tumor cells by TLR ligands in situ. Together, these data emphasize that TLR signaling can directly favor tumor development and further suggest that researchers developing anticancer immunotherapy using TLR7 or TLR8 agonists as adjuvants should take into account the expression of these TLRs in lung tumor cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20237413      PMCID: PMC2846035          DOI: 10.1172/JCI36551

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  68 in total

1.  Chlamydia pneumoniae infection and risk of lung cancer.

Authors:  Alyson J Littman; Emily White; Lisa A Jackson; Mark D Thornquist; Charlotte A Gaydos; Gary E Goodman; Thomas L Vaughan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-10       Impact factor: 4.254

Review 2.  Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists.

Authors:  Holger Kanzler; Franck J Barrat; Edith M Hessel; Robert L Coffman
Journal:  Nat Med       Date:  2007-05       Impact factor: 53.440

Review 3.  Immune surveillance of tumors.

Authors:  Jeremy B Swann; Mark J Smyth
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

4.  NF-kappaB functions as a tumour promoter in inflammation-associated cancer.

Authors:  Eli Pikarsky; Rinnat M Porat; Ilan Stein; Rinat Abramovitch; Sharon Amit; Shafika Kasem; Elena Gutkovich-Pyest; Simcha Urieli-Shoval; Eithan Galun; Yinon Ben-Neriah
Journal:  Nature       Date:  2004-08-25       Impact factor: 49.962

5.  Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling.

Authors:  Bo Huang; Jie Zhao; Shiqian Shen; Hongxing Li; Kai-Li He; Guan-Xin Shen; Lloyd Mayer; Jay Unkeless; Dong Li; Ye Yuan; Gui-Mei Zhang; Huabao Xiong; Zuo-Hua Feng
Journal:  Cancer Res       Date:  2007-05-01       Impact factor: 12.701

6.  Prior lung disease and risk of lung cancer in a large prospective study.

Authors:  Alyson J Littman; Mark D Thornquist; Emily White; Lisa A Jackson; Gary E Goodman; Thomas L Vaughan
Journal:  Cancer Causes Control       Date:  2004-10       Impact factor: 2.506

7.  The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis.

Authors:  Hui Xiao; Muhammet Fatih Gulen; Jinzhong Qin; Jianhong Yao; Katarzyna Bulek; Danielle Kish; Cengiz Zubeyir Altuntas; David Wald; Caixia Ma; Hang Zhou; Vincent K Tuohy; Robert L Fairchild; Carol de la Motte; Daniel Cua; Bruce A Vallance; Xiaoxia Li
Journal:  Immunity       Date:  2007-03-29       Impact factor: 31.745

8.  Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis.

Authors:  Kazuhide Watanabe; Yasuhiro Hasegawa; Hiroshi Yamashita; Kazue Shimizu; Yuanying Ding; Mayumi Abe; Hideki Ohta; Keiichi Imagawa; Kanji Hojo; Hideo Maki; Hikaru Sonoda; Yasufumi Sato
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

9.  Cell proliferation and survival induced by Toll-like receptors is antagonized by type I IFNs.

Authors:  Uzma A Hasan; Christophe Caux; Ivan Perrot; Anne-Claire Doffin; Christine Menetrier-Caux; Giorgio Trinchieri; Massimo Tommasino; Jaromir Vlach
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-26       Impact factor: 11.205

Review 10.  At the crossroads of inflammation and cancer.

Authors:  Hans Clevers
Journal:  Cell       Date:  2004-09-17       Impact factor: 41.582

View more
  79 in total

1.  Update in lung cancer and oncological disorders 2010.

Authors:  Balazs Halmos; Charles A Powell
Journal:  Am J Respir Crit Care Med       Date:  2011-08-01       Impact factor: 21.405

Review 2.  Radiation takes its Toll.

Authors:  Josephine A Ratikan; Ewa D Micewicz; Michael W Xie; Dörthe Schaue
Journal:  Cancer Lett       Date:  2015-03-25       Impact factor: 8.679

3.  Autophagy facilitates TLR4- and TLR3-triggered migration and invasion of lung cancer cells through the promotion of TRAF6 ubiquitination.

Authors:  Zhenzhen Zhan; Xuefeng Xie; Hao Cao; Xiaohui Zhou; Xu Dong Zhang; Huimin Fan; Zhongmin Liu
Journal:  Autophagy       Date:  2013-12-04       Impact factor: 16.016

4.  Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer.

Authors:  Satoshi Okazaki; Sebastian Stintzing; Yu Sunakawa; Shu Cao; Wu Zhang; Dongyun Yang; Yan Ning; Satoshi Matsusaka; Martin D Berger; Yuji Miyamoto; Mitsukuni Suenaga; Marta Schirripa; Jordan D West; Roel Gopez; Tsuji Akihito; Wataru Ichikawa; Volker Heinemann; R William DePaolo; Heinz-Josef Lenz
Journal:  Int J Cancer       Date:  2017-06-21       Impact factor: 7.396

5.  Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab.

Authors:  Satoshi Okazaki; Fotios Loupakis; Sebastian Stintzing; Shu Cao; Wu Zhang; Dongyun Yang; Yan Ning; Yu Sunakawa; Stefan Stremitzer; Satoshi Matsusaka; Martin D Berger; Anish Parekh; Jordan D West; Yuji Miyamoto; Mitsukuni Suenaga; Marta Schirripa; Chiara Cremolini; Alfredo Falcone; Volker Heinemann; R William DePaolo; Heinz-Josef Lenz
Journal:  Mol Cancer Ther       Date:  2016-05-11       Impact factor: 6.261

6.  Toll-like receptor-2/6 and Toll-like receptor-9 agonists suppress viral replication but not airway hyperreactivity in guinea pigs.

Authors:  Matthew G Drake; Scott E Evans; Burton F Dickey; Allison D Fryer; David B Jacoby
Journal:  Am J Respir Cell Mol Biol       Date:  2013-06       Impact factor: 6.914

Review 7.  The therapeutic potential of Toll-like receptor 7 stimulation in asthma.

Authors:  Matthew G Drake; Elad H Kaufman; Allison D Fryer; David B Jacoby
Journal:  Inflamm Allergy Drug Targets       Date:  2012-12

Review 8.  Immunogenic cell death and DAMPs in cancer therapy.

Authors:  Dmitri V Krysko; Abhishek D Garg; Agnieszka Kaczmarek; Olga Krysko; Patrizia Agostinis; Peter Vandenabeele
Journal:  Nat Rev Cancer       Date:  2012-11-15       Impact factor: 60.716

9.  High expression of Toll-like receptor 5 correlates with better prognosis in non-small-cell lung cancer: an anti-tumor effect of TLR5 signaling in non-small cell lung cancer.

Authors:  Hui Zhou; Jian-hua Chen; Jun Hu; Yong-zhong Luo; Fang Li; Ling Xiao; Mei-zuo Zhong
Journal:  J Cancer Res Clin Oncol       Date:  2014-02-19       Impact factor: 4.553

Review 10.  TLR agonists: our best frenemy in cancer immunotherapy.

Authors:  Sabina Kaczanowska; Ann Mary Joseph; Eduardo Davila
Journal:  J Leukoc Biol       Date:  2013-03-08       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.